Trial intelligence / Profile preview

Motavizumab for children hospitalized with RSV illness

NCT00421304Phase 2Completed

Sponsor
MedImmune
Start
Jan 2007
Primary completion
Sep 2009
Modality
Recombinant Proteins and Enzymes, Monoclonal Antibodies
Countries
5
01

Overview

A Phase 2 trial of motavizumab in respiratory syncytial virus infection (RSV), sponsored by MedImmune. Started Jan 2007; status: completed.

02

Drugs

motavizumab
03

Conditions

respiratory syncytial virus infection (RSV)

Beyond the preview

Go deeper on NCT00421304.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00421304.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call